Exchange: NASDAQ·Updated 03:39 PM EST

JDOC News

News
all
press releases
Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.
Stocktwits
Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.
Stocktwits
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.
Stocktwits

Advertisement|Remove ads.